How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,764 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. [Dimethyl fumarate (psoriasis) - benefit assessment according to õ35a Social Code Book V]

[Dimethyl fumarate (psoriasis) - benefit assessment according to õ35a Social Code Book V] Dimethylfumarat (psoriasis vulgaris): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-49 [Dimethyl fumarate (psoriasis) - benefit assessment according to §35a Social Code Book V] Dimethylfumarat (psoriasis vulgaris): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-49 [Dimethyl fumarate (psoriasis) - benefit assessment according to §35a Social Code Book V] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dimethylfumarat (psoriasis vulgaris): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-49. [Dimethyl fumarate (psoriasis) - benefit assessment according to §35a

2018 Health Technology Assessment (HTA) Database.

62. [Brodalumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V]

[Brodalumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V] Brodalumab (Plaque-Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-42; version 1.1 [Brodalumab (plaque psoriasis) – benefit assessment according to §35a Social Code Book V] Brodalumab (Plaque-Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-42; version 1.1 [Brodalumab (plaque psoriasis) – benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Brodalumab (Plaque-Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-42; version 1.1. [Brodalumab (plaque psoriasis) – benefit assessment

2018 Health Technology Assessment (HTA) Database.

63. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Duarte A, Mebrahtu T, Goncalves P S, Harden M, Murphy R, Palmer S, Woolacott (...) N, Rodgers M & Rothery C. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Duarte A, Mebrahtu T, Goncalves P S, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M & Rothery C.. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technology

2018 Health Technology Assessment (HTA) Database.

64. Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness

Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Pimecrolimus (...) for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Published on: September 25, 2017 Project Number: RC0919-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of pimecrolimus for the treatment of adults with atopic dermatitis? What is the clinical effectiveness of pimecrolimus for the treatment of adults with seborrheic dermatitis? What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

65. Tacrolimus for the Treatment of Adults with Psoriasis or Vitiligo: A Review of the Clinical and Cost-Effectiveness

Tacrolimus for the Treatment of Adults with Psoriasis or Vitiligo: A Review of the Clinical and Cost-Effectiveness Tacrolimus for the Treatment of Adults with Psoriasis or Vitiligo: A Review of the Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Tacrolimus for the Treatment of Adults with Psoriasis or Vitiligo: A Review of the Clinical and Cost-Effectiveness Tacrolimus for the Treatment of Adults with Psoriasis or Vitiligo: A Review of the Clinical and Cost (...) -Effectiveness Published on: October 11, 2017 Project Number: RC0920-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of tacrolimus for the treatment of adults with psoriasis? What is the clinical effectiveness of tacrolimus for the treatment of adults with vitiligo? What is the cost-effectiveness of tacrolimus for the treatment of adults with psoriasis? What is the cost-effectiveness of tacrolimus

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

66. Tremfya - guselkumab - Psoriasis, moderate to severe plaque

Tremfya - guselkumab - Psoriasis, moderate to severe plaque guselkumab | CADTH.ca Find the information you need guselkumab guselkumab Last Updated: April 5, 2018 Result type: Reports Project Number: SR0530-000 Product Line: Generic Name: guselkumab Brand Name: Tremfya Manufacturer: Janssen Inc. Indications: Psoriasis, moderate to severe plaque Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: February 21, 2018 Recommendation Type: Reimburse with clinical

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

67. Siliq - brodalumab - Psoriasis, moderate to severe plaque

Siliq - brodalumab - Psoriasis, moderate to severe plaque brodalumab | CADTH.ca Find the information you need brodalumab brodalumab Last Updated: July 16, 2018 Result type: Reports Project Number: SR0547-000 Product Line: Generic Name: brodalumab Brand Name: Siliq Manufacturer: Valeant Canada LP Indications: Psoriasis, moderate to severe plaque Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: June 20, 2018 Recommendation Type: Reimburse with clinical (...) period ended and validation of redacted CDR review report(s) received June 13, 2018 CDEC Final Recommendation issued to applicant and drug plans June 20, 2018 CDEC Final Recommendation posted June 22, 2018 Final CDR review report(s) and patient input posted July 16, 2018 Tags dermatology, psoriasis, brodalumab; siliq; psoriases; psoriatic Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

68. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2018 Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value Condition Update Evidence Report June 12, 2018 Prepared for: ©Institute for Clinical and Economic Review, 2018 Page i Evidence Report: Targeted Immunomodulators for Plaque Psoriasis | Condition Update ICER Staff/Consultants (...) Immunomodulators for Plaque Psoriasis | Condition Update About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. The funding for this report comes from government grants and non-profit foundations, with the largest single funder being the Laura and John Arnold Foundation. No funding

2018 California Technology Assessment Forum

69. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2018 Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value Condition Update Final Evidence Report August 03, 2018 Prepared for: ©Institute for Clinical and Economic Review, 2018 Page i Final Evidence Report: Plaque Psoriasis Condition Update ICER Staff/Consultants University of Washington (...) ii Final Evidence Report: Plaque Psoriasis Condition Update About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. The funding for this report comes from government grants and non-profit foundations, with the largest single funder being the Laura and John Arnold

2018 California Technology Assessment Forum

70. Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease

Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease '); } else { document.write(' '); } ACE | Infliximab for the treatment of rheumatoid arthritis ankylosing spondylitis psoriatic arthritis plaque psoriasis ulcerative colitis and crohns disease Search > > Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis (...) and Crohn's disease - Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease Published on 1 March 2018 Guidance Recommendation The Ministry of Health’s Drug Advisory Committee has recommended: Infliximab biosimilar (Remsima) 100mg vial for the treatment of: Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, ulcerative

2018 Publication 4890906

71. [Secukinumab (plaque psoriasis) - addendum to Commission A17-08]

[Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31 [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31 [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31. [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 529. 2017 Final publication URL Indexing Status Subject indexing

2017 Health Technology Assessment (HTA) Database.

72. [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07]

[Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30 [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30 [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30. [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 528. 2017 Final publication URL Indexing Status Subject indexing assigned

2017 Health Technology Assessment (HTA) Database.

73. [Secukinumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V (new scientific findings)]

[Secukinumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V (new scientific findings)] Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung [Secukinumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)] Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung [Secukinumab (plaque (...) psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue

2017 Health Technology Assessment (HTA) Database.

74. [Ixekizumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V]

[Ixekizumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V] Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07 [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07 [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und (...) Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07. [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Cologne

2017 Health Technology Assessment (HTA) Database.

75. Topical treatments for scalp psoriasis. (Full text)

Topical treatments for scalp psoriasis. People with chronic plaque psoriasis often have lesions on the scalp. Hair makes the scalp difficult to treat and the adjacent facial skin is particularly sensitive to topical treatments.To assess the efficacy and safety of topical treatments for scalp psoriasis.We searched the following databases up to August 2015: the Cochrane Skin Group Specialised Register, CENTRAL (2015, Issue 7), MEDLINE (from 1946), EMBASE (from 1974) and LILACS (from 1982). We (...) also searched five trials registers, screened abstracts of six psoriasis-specific conferences and checked the reference lists of included studies for further references to relevant randomised controlled trials.Randomised controlled trials (RCTs) with a parallel-group, cross-over or within-patient design of topical treatments for people of all ages with scalp psoriasis.Two authors independently carried out study selection, data extraction and 'Risk of bias' assessment. Disagreements were settled

2016 Cochrane PubMed

76. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2016 Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value Final Evidence Report December 2, 2016 Prepared for ©Institute for Clinical and Economic Review, 2016 Page ii Final Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table (...) Institute for Clinical and Economic Review, 2016 Page iii Final Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table of Contents Disclosure Statement: Dr. Linder owns stock in Amgen, Biogen, and Eli Lily, has contingent value rights in Sanofi Genzyme (related to alemtuzumab for multiple sclerosis); in the past 3 years, Dr. Linder has received grant support from Astellas Pharma on an unrelated topic (overactive bladder) and Clintrex, which

2017 California Technology Assessment Forum

77. Biological therapies for psoriasis do not increase serious infection risk

Biological therapies for psoriasis do not increase serious infection risk Biological therapies for psoriasis do not increase serious infection risk Discover Portal Discover Portal Biological therapies for psoriasis do not increase serious infection risk Published on 23 January 2018 doi: People with psoriasis who take an immune-modulating treatment are no more likely to get serious infections than people taking standard therapies. There are fears that these biological therapies raise the risk (...) of serious infections and this has discouraged their use. They are recommended by NICE for moderate to severe psoriasis. Previous studies have reached conflicting conclusions, making it hard to advise on the true risk. This study used a large database of people with psoriasis from the UK and Ireland. It compared serious infection risk of the biological therapies (etanercept, adalimumab or ustekinumab) with non-biological therapies, after accounting for factors such as other illnesses. It found none

2019 NIHR Dissemination Centre

78. Biologic therapy for psoriasis

Biologic therapy for psoriasis British Association of Dermatologists FULL VERSION Guidelines for biologic therapy for psoriasis Methods, evidence and recommendations April 2017 NICE has renewed accreditation of the process used by the British Association of Dermatologists to produce clinical guidelines. The renewed accreditation is valid until 31 May 2021 and applies to guidance produced using the processes described in Updated guidance for writing a British Association of Dermatologists (...) : Evidence tables clinical studies 227 Appendix F: Forest plots 296 Appendix G: Stakeholders 342 Appendix H: Study selection flow charts 343 Appendix I: GRADE tables 349 Appendix J: Choice of biologic treatment for psoriasis (decision aid) 385 Appendix K: Groups at increased risk of tuberculosis, hepatitis B, hepatitis C and HIV 389 British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 1 Guideline Development Group members Name Role CLINICAL Ms Tracy Bale British

2017 British Association of Dermatologists

79. Topical steroids better than vitamin D for treating scalp psoriasis

Topical steroids better than vitamin D for treating scalp psoriasis Topical steroids better than vitamin D for treating scalp psoriasis Discover Portal Discover Portal Topical steroids better than vitamin D for treating scalp psoriasis Published on 14 June 2016 doi: Topical steroids applied to the scalp were more effective and safer for treating psoriasis than topical vitamin D alone. Using steroids in combination with vitamin D was statistically better than using a steroid alone (...) , but the difference was not considered clinically important. The combination ointment costs almost £20 for 30g compared to a 30g tube of typical steroid ointment which costs about £4. Scalp psoriasis is a common condition that can be itchy and embarrassing for many. A variety of topical lotions, solutions or gels are available to treat the condition, so this review of published research aimed to help doctors and patients find out which was the most effective and safest option. This systematic review found 59

2019 NIHR Dissemination Centre

80. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites (...) therapy for psoriasis 2017. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning VA, Warren RB, Exton LS, Mohd Mustapa MF. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628-36. [17 references] This is the current release of the guideline. This guideline updates

2017 National Guideline Clearinghouse (partial archive)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>